• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吲哚菁绿血管造影:息肉状脉络膜血管病变的光动力治疗引导

Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.

作者信息

Otani Atsushi, Sasahara Manabu, Yodoi Yuko, Aikawa Hiroko, Tamura Hiroshi, Tsujikawa Akitaka, Yoshimura Nagahisa

机构信息

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

出版信息

Am J Ophthalmol. 2007 Jul;144(1):7-14. doi: 10.1016/j.ajo.2007.03.014. Epub 2007 Apr 30.

DOI:10.1016/j.ajo.2007.03.014
PMID:17467649
Abstract

PURPOSE

To report the 12-month follow-up results of subfoveal polypoidal choroidal vasculopathy (PCV) patients treated with indocyanine green angiography (ICGA)-guided photodynamic therapy (PDT).

DESIGN

Interventional, noncomparative cases series.

METHODS

A retrospective analysis of the clinical and angiographic data related to 47 PCV eyes that were followed up for 12 months was carried out. The greatest linear dimension (GLD) for PDT was determined based on the ICGA findings. Optical coherence tomography (OCT) also was used to evaluate the therapeutic effects.

RESULTS

The mean logarithm of the minimum angle of resolution visual acuity (VA; 0.58 +/- 0.37) significantly improved to 0.53 +/- 0.38 at three months (P = .04) and to 0.46 +/- 0.40 at 12 months (P = .02). The average ICGA GLD (2682.3 +/- 1026.9 mm) was significantly (P = .0001) smaller than the presumed fluorescein angiography (FA) GLD (4043.6 +/- 1914.8 mm). In more than 80% of cases, complete resolution of retinal exudative changes was observed. Although polypoidal vascular lesions disappeared in 82.2% of eyes, the branched vascular networks showed little change. The initial VA and GLD had little correlation with the VA outcome.

CONCLUSIONS

ICGA-guided PDT reduces the size of laser exposure and is an effective treatment for PCV. Because PCV may appear as occult choroidal neovascularization (CNV) on FA, PCV should be diagnosed using ICGA before treatment because PCV may respond differently than CNV to appropriate treatment.

摘要

目的

报告吲哚菁绿血管造影(ICGA)引导下光动力疗法(PDT)治疗中心凹下息肉样脉络膜血管病变(PCV)患者的12个月随访结果。

设计

干预性、非对照病例系列。

方法

对47只接受了12个月随访的PCV患眼的临床和血管造影数据进行回顾性分析。根据ICGA检查结果确定PDT的最大线性尺寸(GLD)。光学相干断层扫描(OCT)也用于评估治疗效果。

结果

最小分辨角视力(VA)的平均对数值(0.58±0.37)在3个月时显著提高至0.53±0.38(P = 0.04),在12个月时提高至0.46±0.40(P = 0.02)。平均ICGA GLD(2682.3±1026.9 mm)显著(P = 0.0001)小于推测的荧光素血管造影(FA)GLD(4043.6±1914.8 mm)。在超过80%的病例中,观察到视网膜渗出性改变完全消退。虽然82.2%的患眼中息肉样血管病变消失,但分支血管网变化不大。初始视力和GLD与视力预后几乎没有相关性。

结论

ICGA引导下的PDT可减小激光照射面积,是治疗PCV的有效方法。由于PCV在FA上可能表现为隐匿性脉络膜新生血管(CNV),因此在治疗前应使用ICGA诊断PCV,因为PCV对适当治疗的反应可能与CNV不同。

相似文献

1
Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.吲哚菁绿血管造影:息肉状脉络膜血管病变的光动力治疗引导
Am J Ophthalmol. 2007 Jul;144(1):7-14. doi: 10.1016/j.ajo.2007.03.014. Epub 2007 Apr 30.
2
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.日本患者年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法一年期疗效
Ophthalmology. 2008 Jan;115(1):141-6. doi: 10.1016/j.ophtha.2007.02.031. Epub 2007 Jun 20.
3
One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.减少强度的光动力疗法治疗息肉样脉络膜血管病变的一年疗效。
Am J Ophthalmol. 2010 Mar;149(3):465-71.e1. doi: 10.1016/j.ajo.2009.09.020. Epub 2009 Dec 30.
4
Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.少能量频域光动力疗法治疗息肉状脉络膜血管病变的两年结果。
Am J Ophthalmol. 2013 Jan;155(1):96-102.e1. doi: 10.1016/j.ajo.2012.06.027. Epub 2012 Sep 18.
5
Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.光动力疗法联合玻璃体内注射雷珠单抗治疗息肉状脉络膜血管病变。
Am J Ophthalmol. 2012 Jan;153(1):68-80.e1. doi: 10.1016/j.ajo.2011.07.001. Epub 2011 Sep 9.
6
Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.息肉状脉络膜血管病变光动力疗法的两年结果
Am J Ophthalmol. 2008 Oct;146(4):513-519. doi: 10.1016/j.ajo.2008.05.025. Epub 2008 Jul 9.
7
Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.眼内雷珠单抗联合维替泊芬光动力疗法治疗息肉状脉络膜血管病变。
Retina. 2011 Jul-Aug;31(7):1287-93. doi: 10.1097/IAE.0b013e3182003ccd.
8
Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy.光动力治疗后息肉状脉络膜血管病变的显著血管变化。
Br J Ophthalmol. 2008 Jul;92(7):936-40. doi: 10.1136/bjo.2007.132357.
9
Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.光动力疗法联合维替泊芬治疗息肉样脉络膜血管病变:3 年随访结果。
Retina. 2010 Sep;30(8):1197-205. doi: 10.1097/IAE.0b013e3181d37486.
10
Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy.采用微视野计1测量息肉样脉络膜血管病变光动力治疗后的中心视网膜敏感度。
Am J Ophthalmol. 2007 Jun;143(6):984-994. doi: 10.1016/j.ajo.2007.01.026. Epub 2007 Mar 6.

引用本文的文献

1
The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular Degeneration.光动力疗法治疗年龄相关性黄斑变性的过去、现在和未来展望
J Clin Med. 2025 Feb 13;14(4):1240. doi: 10.3390/jcm14041240.
2
Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy.系统评价与网络荟萃分析抗血管内皮生长因子治疗息肉状脉络膜血管病变。
Sci Rep. 2021 Feb 2;11(1):2735. doi: 10.1038/s41598-021-82316-y.
3
Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.
特发性息肉状脉络膜血管病变:文献复习及现行治疗方法的临床更新。
Int Ophthalmol. 2021 Feb;41(2):753-765. doi: 10.1007/s10792-020-01620-0. Epub 2020 Oct 20.
4
Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities.抗 VEGF 治疗在新生血管性 AMD 中的不完全反应:探索疾病机制和治疗机会。
Prog Retin Eye Res. 2021 May;82:100906. doi: 10.1016/j.preteyeres.2020.100906. Epub 2020 Oct 3.
5
Optical coherence tomography angiography-guided photodynamic therapy for extrafoveal choroidal neovascularization.光学相干断层扫描血管造影引导下的光动力疗法治疗黄斑中心凹外脉络膜新生血管
Digit J Ophthalmol. 2020 Mar 31;26(1):1-7. doi: 10.5693/djo.02.2020.01.001. eCollection 2020 Jan.
6
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy.雷珠单抗对息肉状脉络膜血管病变患者的治疗效果。
BMC Ophthalmol. 2019 Jul 19;19(1):153. doi: 10.1186/s12886-019-1156-4.
7
Polypoidal choroidal vasculopathy: An update on current management and review of literature.息肉样脉络膜血管病变:当前治疗进展及文献综述
Taiwan J Ophthalmol. 2019 Apr-Jun;9(2):72-92. doi: 10.4103/tjo.tjo_35_18.
8
Polypoidal choroidal vasculopathy: a comprehensive clinical update.息肉样脉络膜血管病变:临床综合进展
Ther Adv Ophthalmol. 2019 Feb 27;11:2515841419831152. doi: 10.1177/2515841419831152. eCollection 2019 Jan-Dec.
9
One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data.中国人群中玻璃体内注射康柏西普联合挽救疗法治疗息肉状脉络膜血管病变的一年期疗效:真实临床数据
Int J Ophthalmol. 2019 Jan 18;12(1):51-57. doi: 10.18240/ijo.2019.01.08. eCollection 2019.
10
Polypoidal choroidal vasculopathy: Pearls in diagnosis and management.息肉样脉络膜血管病变:诊断与治疗要点。
Indian J Ophthalmol. 2018 Jul;66(7):896-908. doi: 10.4103/ijo.IJO_1136_17.